Sponsors (11)
The bill increases medication safety and equitable access by requiring standardized printed patient medication information at dispensing, but does so at the cost of added compliance and production burdens for manufacturers and pharmacies, potential delays or rushed implementation, and greater paper waste.
Patients (especially seniors and people with chronic conditions) will receive clear, standardized printed medication information with each prescription, reducing adverse drug events, ER visits, and hospitalizations.
Standardized PMIs will create consistent, easy-to-use labeling across products, helping pharmacists, health systems, and caregivers reduce dispensing errors and improve communication about safe use.
Clear, research-based patient PMIs can improve medication understanding and adherence, which may lower avoidable health care use and costs for patients and payers over time.
Drug manufacturers and pharmacies will face increased compliance, production, packaging, and printing costs to produce and supply standardized printed PMIs for every prescription.
Smaller manufacturers may face disproportionate burdens (research, development, approval, and printing costs), potentially slowing product launches or reducing market competition.
Requiring printed materials for every prescription risks increasing paper waste and duplicating digital efforts, creating a negative environmental impact unless coordinated with electronic systems.
Based on analysis of 3 sections of legislative text.
Requires FDA to require standardized printed patient medication information for prescription drugs, sets content/format/supply rules, and makes failure to provide it a misbranding violation.
Introduced September 4, 2025 by Cliff Bentz · Last progress September 4, 2025
Requires the Food and Drug Administration to issue final regulations within one year that make a standardized printed patient medication information (PMI) leaflet mandatory for prescription drugs dispensed outside hospitals. Manufacturers must create and submit the PMI with approval applications; FDA must approve content, format, and distribution rules; pharmacies must provide one printed copy with each dispensed prescription. Failure to supply PMI as required is treated as misbranding under the FD&C Act. The required PMI must be scientifically accurate, nonpromotional, written in plain language with graphics, meet minimum font/format/color standards, list key safety and use information (including approved uses, directions, warnings, interactions, storage/disposal, manufacturer contact, and an adverse event reporting link), be kept current, and be supported by patient comprehension research showing better understanding and improved adherence/outcomes. The law also allows class-wide communications and mandates timely updates approved by FDA.